Vernakalant for the rapid conversion of recent onset atrial fibrillation to sinus rhythm (terminated appraisal)

NICE is unable to make a recommendation on vernakalant (Brinavess) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults. This is because Correvio Ltd did not provide an evidence submission.

Last reviewed: 17 February 2021

Next review: We will review this decision if the company decides to make a submission.

Guidance development process

How we develop NICE technology appraisal guidance